Ingevity Corp (NGVT) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Ingevity’s revenue went from $908M in fiscal 2016 to $1.2B in fiscal 2025, growth of about 2.8% a year.
Net income in fiscal 2025 was -$167M, a net margin of -14.3%; the best year in this period was 2022 with $212M.
Over the twelve months to September 30, 2026, revenue was $1.1B and net income $60M.
Free cash flow was $274M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 14% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.2B | $1.2B | $1.2B | $1.7B | $1.4B | $1.2B | $1.3B | $1.1B | $972M | $908M |
| Gross profit | $476M | $462M | $465M | $445M | $570M | $513M | $466M | $482M | $417M | $329M | $274M |
| Operating income | $44M | $419M | $426M | $423M | $453M | $422M | $398M | $397M | $320M | $243M | $164M |
| Net income | $60M | -$167M | -$430M | -$5M | $212M | $118M | $181M | $184M | $169M | $126M | $35M |
| EPS (diluted) | $1.73 | $-4.61 | $-11.85 | $-0.15 | $5.50 | $2.95 | $4.37 | $4.35 | $3.97 | $2.97 | $0.83 |
| R&D | $28M | $28M | $24M | $25M | $30M | $26M | $23M | $20M | $22M | $20M | $18M |
| Revenue growth | — | −2.7% | −1.3% | −27.1% | +19.9% | +14.4% | −5.9% | +14.1% | +16.6% | +7.1% | −5.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $180M | $331M | $129M | $205M | $313M | $293M | $352M | $276M | $252M | $174M | $128M |
| Capital spending | -$58M | -$58M | -$78M | -$110M | -$142M | -$104M | -$82M | -$115M | -$94M | -$53M | -$57M |
| Free cash flow | $123M | $274M | $51M | $95M | $171M | $190M | $270M | $161M | $158M | $122M | $71M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $156M | $56M | $0 | $92M | $145M | $109M | $88M | $6M | $47M | $7M | $0 |
| Stock-based pay | $18M | $18M | $12M | $11M | $16M | $12M | $8M | $12M | $12M | $10M | $5M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $78M | $68M | $96M | $77M | $275M | $258M | $56M | $78M | $88M | $30M |
| Debt | — | $1.2B | $1.5B | $1.5B | $1.5B | $1.3B | $1.4B | $1.3B | $759M | $455M | $492M |
| Equity | — | $30M | $195M | $631M | $698M | $674M | $642M | $531M | $339M | $264M | $127M |
| Total assets | — | $1.7B | $2.0B | $2.6B | $2.7B | $2.5B | $2.3B | $2.1B | $1.3B | $930M | $833M |
| Shares (diluted) | 35M | 36M | 36M | 37M | 38M | 40M | 42M | 42M | 43M | 43M | 42M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 42.0% | 39.5% | 38.7% | 36.6% | 34.2% | 36.9% | 38.3% | 37.3% | 36.8% | 33.8% | 30.2% |
| Operating margin | 3.9% | 35.9% | 35.5% | 34.8% | 27.1% | 30.3% | 32.7% | 30.7% | 28.3% | 25.0% | 18.0% |
| Net margin | 5.3% | -14.3% | -35.9% | -0.4% | 12.7% | 8.5% | 14.9% | 14.2% | 14.9% | 13.0% | 3.9% |
| FCF margin | 10.8% | 23.4% | 4.2% | 7.8% | 10.2% | 13.6% | 22.2% | 12.4% | 14.0% | 12.5% | 7.8% |
| ROIC | — | 26.0% | 22.3% | 15.9% | 15.9% | 15.3% | 15.3% | 17.4% | 23.9% | 28.0% | 13.5% |
| ROE | — | -562.6% | -220.4% | -0.9% | 30.3% | 17.5% | 28.2% | 34.6% | 49.9% | 47.9% | 27.7% |
Frequently asked questions
What is Ingevity’s annual revenue?
$1.2B in fiscal 2025 and $1.1B over the twelve months to September 30, 2026.
How much profit does Ingevity make?
Net income was -$167M in fiscal 2025 (net margin -14.3%).
Is Ingevity’s revenue growing?
No: revenue fell 2.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.